2019冠状病毒病与原发性抗体缺陷。对米洛塔等人的评论。原发性抗体缺陷患者的2019冠状病毒病临床结局。2023年，，109。
Coronavirus Disease 2019 and Primary Antibody Deficiencies. Comment on Milota et al. Clinical Outcome of Coronavirus Disease 2019 in Patients with Primary Antibody Deficiencies. 2023, , 109.
作者信息
Özdemir Öner
机构信息
Division of Allergy and Immunology, Department of Pediatrics, Research and Training Hospital, Medical Faculty, Sakarya University, Adapazarı, Sakarya 54100, Türkiye.
出版信息
Pathogens. 2023 Mar 29;12(4):532. doi: 10.3390/pathogens12040532.
Abstract
We have read the article titled 'Clinical Outcome of Coronavirus Disease 2019 in Patients with Primary Antibody Deficiencies' by Milota et al. with great interestl [...].
摘要
我们饶有兴趣地阅读了米洛塔等人撰写的题为《原发性抗体缺陷患者的2019冠状病毒病临床结局》的文章[……]
相似文献
1
Coronavirus Disease 2019 and Primary Antibody Deficiencies. Comment on Milota et al. Clinical Outcome of Coronavirus Disease 2019 in Patients with Primary Antibody Deficiencies. 2023, , 109.2019冠状病毒病与原发性抗体缺陷。对米洛塔等人的评论。原发性抗体缺陷患者的2019冠状病毒病临床结局。2023年，，109。
Pathogens. 2023 Mar 29;12(4):532. doi: 10.3390/pathogens12040532.
2
Clinical Outcome of Coronavirus Disease 2019 in Patients with Primary Antibody Deficiencies.原发性抗体缺陷患者的2019冠状病毒病临床结局
Pathogens. 2023 Jan 9;12(1):109. doi: 10.3390/pathogens12010109.
3
Comment on Rochmah et al. Economic Burden of Stroke Disease: A Systematic Review. 2021, , 7552.评论 Rochmah 等人的《卒中疾病的经济负担：系统评价》。2021 年， ，7552。
Int J Environ Res Public Health. 2022 Mar 30;19(7):4095. doi: 10.3390/ijerph19074095.
4
Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Combination Therapy in Patients With Coronavirus Disease 2019 and Primary Antibody Deficiency.严重急性呼吸综合征冠状病毒 2 单克隆抗体联合治疗新型冠状病毒病 2019 患者和原发性抗体缺陷。
J Infect Dis. 2022 Mar 2;225(5):820-824. doi: 10.1093/infdis/jiab554.
5
Comment on "Epidemiological and clinical characteristics of heart transplant recipients during the 2019 coronavirus outbreak in Wuhan, China" by Ren et al.关于任等人所著的《中国武汉2019年冠状病毒爆发期间心脏移植受者的流行病学和临床特征》的评论
J Heart Lung Transplant. 2020 Jul;39(7):729. doi: 10.1016/j.healun.2020.04.002. Epub 2020 Apr 11.
6
Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency.抗体缺陷患者对 SARS-CoV-2 的强大抗体和 T 细胞反应。
J Clin Immunol. 2021 Aug;41(6):1146-1153. doi: 10.1007/s10875-021-01046-y. Epub 2021 May 13.
7
Dealing with the Problem of Monotone Likelihood in the Inflation of Estimated Effects in Clinical Studies. Comment on Hasegawa et al. Impact of Blood Type O on Mortality of Sepsis Patients: A Multicenter Retrospective Observational Study. 2020, , 826.应对临床研究中估计效应膨胀问题中的单调似然性问题。对长谷川等人的评论。血型O对脓毒症患者死亡率的影响：一项多中心回顾性观察研究。2020年，，826。
Diagnostics (Basel). 2022 Sep 23;12(10):2295. doi: 10.3390/diagnostics12102295.
8
Clinical characteristics and plasma antibody titer of patients with COVID-19 in Zhejiang, China.中国浙江 COVID-19 患者的临床特征和血浆抗体滴度。
J Zhejiang Univ Sci B. 2020;21(12):955-960. doi: 10.1631/jzus.B2000593.
9
Comment on "Sourdough Fermentation Degrades Wheat Alpha-Amylase/Trypsin Inhibitor (ATI) and Reduces Pro-Inflammatory Activity". Foods 2020, , 943.关于《酸面团发酵降解小麦α-淀粉酶/胰蛋白酶抑制剂（ATI）并降低促炎活性》的评论。《食品》2020年，，943。
Foods. 2020 Oct 3;9(10):1404. doi: 10.3390/foods9101404.
10
Comment on Piña et al. Ten Approaches That Improve Immunostaining: A Review of the Latest Advances for the Optimization of Immunofluorescence. 2022, , 1426.评 Piña 等人的《十种改善免疫染色的方法：免疫荧光优化最新进展综述》。2022 年， ，1426 页。
Int J Mol Sci. 2022 Apr 15;23(8):4372. doi: 10.3390/ijms23084372.
本文引用的文献
1
Clinical Outcome of Coronavirus Disease 2019 in Patients with Primary Antibody Deficiencies.原发性抗体缺陷患者的2019冠状病毒病临床结局
Pathogens. 2023 Jan 9;12(1):109. doi: 10.3390/pathogens12010109.
2
Risk Factors for Severe COVID-19 and Hospital Admission in Patients With Inborn Errors of Immunity - Results From a Multicenter Nationwide Study.先天性免疫缺陷患者发生重症 COVID-19 和住院的危险因素：一项多中心全国性研究结果
Front Immunol. 2022 Feb 28;13:835770. doi: 10.3389/fimmu.2022.835770. eCollection 2022.
3
COVID-19 and hereditary angioedema: Incidence, outcomes, and mechanistic implications.COVID-19 与遗传性血管性水肿：发病率、结局及机制影响。
Allergy Asthma Proc. 2021 Nov 1;42(6):506-514. doi: 10.2500/aap.2021.42.210083.
4
Asthma Phenotypes and COVID-19 Risk: A Population-based Observational Study.哮喘表型与 COVID-19 风险：基于人群的观察性研究。
Am J Respir Crit Care Med. 2022 Jan 1;205(1):36-45. doi: 10.1164/rccm.202107-1704OC.
5
Effect of COVID-19 on hereditary angioedema activity and quality of life.COVID-19 对遗传性血管性水肿活动和生活质量的影响。
Allergy Asthma Proc. 2021 Sep 1;42(5):403-408. doi: 10.2500/aap.2021.42.210066.
6
Asthma and COVID-19 risk: a systematic review and meta-analysis.哮喘与 COVID-19 风险：系统评价和荟萃分析。
Eur Respir J. 2022 Mar 31;59(3). doi: 10.1183/13993003.01209-2021. Print 2022 Mar.
7
The impact of COVID-19 on patients with asthma.COVID-19 对哮喘患者的影响。
Eur Respir J. 2021 Mar 4;57(3). doi: 10.1183/13993003.03142-2020. Print 2021 Mar.
Zotero 插件